Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: Comparison with an ex vivo annular perfusion chamber model

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 71-78

  Roux, Sébastien ^a   Tschopp, Thomas ^a   Baumgartner, Hans Rudolf ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; NAPSAGATRAN; THROMBIN INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY THROMBOSIS; DOG; FEMALE; HEART PERFUSION; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; THROMBOPLASTIN TIME; THROMBOSIS PREVENTION;

ANIMALS; ANTITHROMBINS; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; MALE; NAPHTHALENES; PARTIAL THROMBOPLASTIN TIME; PERFUSION; PIPERIDINES;

EID: 0030431039     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. BADIMON, L., BADIMON, J. J., LASSILA, R., HERAS, M., CHESEBRO, J. H. AND FUSTER, V.: Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: Effects of hirudins, heparin, and calcium chelation. Blood 78: 423-34, 1991.
2. BANKEN, L., BUBGER, H. U., KRISTIANSEN, S. AND PASQUIER M.: The closed test procedure. Proceedings of the 11th annual meeting of SAS system users in Europe, SAS Institute, Carry, NC, p. 501-503, 1993.
3. BAUMGARTNER, H. R. AND MUGGLI, R.: Adhesion and aggregation: Morphological demonstration and quantitation in vivo and in vitro. In: Platelets in Biology and Pathology. J. L. Gordon, ed., pp 23-60, Elsevier/North Holland Biomedical Press, New York, 1976.
4. BAUMGARTNER, H. R. AND SAKARIASSEN, K. S.: Factors controlling thrombus formation on arterial lesions. Ann. N. Y. Acad. Sci. 464: 162-177, 1985.
5. BAUMGARTNER, H. R., TURITTO, V. T. AND WEISS, H. J., Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. II. Relationships among platelet adhesion, thrombus dimensions, and fibrin formation. J. Lab. Clin. Med. 95: 208-221, 1980.
6. CADROY, Y., MARAGANORE, J. M., HANSON, S. R. AND HARKER, L. A.: Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons. Proc. Natl. Acad. Sci U.S.A. 88: 1177-1181, 1991.
7. CANNON, C. P., MCCABE, C. H., HENRY, T. D , SCHWEIGER, M J., GIBSON, R. S., MUELLER, H. S., BECKER, R. C., KLEIMAN, N. S., HAUGLAND, M., ANDERSON, J. L., SHARAF, B. L., EDWARDS, S. J., ROGERS, W. J., WILLAMS, D. O. AND BRAUNWALD, E.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasmmogen activator and aspirin for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J. Am. Coll. Cardiol. 23: 993-1003, 1994.
8. CARTEAUX, J. P., GAST, A., TSCHOPP, T. AND ROUX, S.: The activated clotting time (ACT) as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 91: 1568-1574, 1995.
9. DIQUÉLOU, A., LEMOZY, S., DUPOUY, D., BONEU, B., SAKARIASSEN, K. AND CADROY, Y.: Effect of blood flow on thrombin generation is dependent on the nature of the thrombogenic surface. Blood 84: 2206-13, 1994.
10. FALK, E.: Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 71: 699-708, 1985.
11. FOLTS, J.: An in vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation 83: IV.3-IV.14, 1991.
12. FREUND, M., MANTZ, F , NICOLINI, P., GACHET, C., MULVIHILL, J., MEYER, L., BERETZ, A. AND CAZENAVE, J. P.: Experimental thrombosis on a collagen coated arterioarterial shunt in rats: A pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Thromb. Haemost. 69: 515-21, 1993.
13. FUCHS, J., MCCABE, C. H., ANTMAN, E. M., BORZAK, S., PALISAITIS, D., HERSON, S., DAUM, R., PALMERI, S., SEQUEIRA, R., SHARMA, G., DIVER, D., WARNICA, W., MUELLER, H., MAGORIEN, R., GOLDBERG, N., LEYA, F., THOMPSON, C., WILLIAMS, D. O., REMETZ, M., CHAKKO, S., HENRY, T., HOCHMAN, J., CHAITMAN, B., CANNON, C. P., FINDLEN, K., ADELMAN, B. AND BRAUNWALD, E.: Hirulog in the treatment of unstable angina: Results of the TIMI 7 trial. J. Am. Coll. Cardiol. 23: 56A, 1994.
14. GAST, A., TSCHOPP, T. B. AND BAUMGARTNER, H. R.: Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler. Thromb. 14: 1466-74, 1994.
15. GAWOSKI, J. M., ARKIN, C. F., BOVILL, T., BRANDT, J., ROCK, W. A., JR. AND TRIPLETT, D. A.: The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Surveys Specimens. Responsiveness, precision and sample effects. Arch. Pathol. Lab. Med. 111: 785-790, 1987.
16. GOLDSMITH, H. L. AND TURITTO, V. T.: Rheological aspects of thrombosis and haemostasis: Basic principles and applications. ICTH-Report-Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis. Thromb. Haemost. 55: 415-35, 1986.
17. GRANGER, C., VAN DER WERF, F., HORRIGAN, M., CALIFF, R., WOODLIEF, L. AND TOPOL, E.: Hemorrhage stroke associated with high aPTTs following thrombolytic therapy and heparin or hirudin (Abstract). J. Am. Coll. Cardiol. (special issue) 310A, 1995.
18. GRANNIS, G. F.: Plasma fibrinogen: Determination, normal values, physiopathologic shifts and fluctuations. Clin. Chem. 16: 486-494, 1970.
19. THE GUSTO IIA INVESTIGATORS: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90: 1631-1637, 1994.
20. HANSON, S. R. AND HARKER, L. A.: Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc. Natl. Acad. Sci. U.S.A. 85: 3184-8, 1988.
21. HERAS, M., CHESEBRO, J. H., PENNY, W. J., BAILEY, K. R., BADIMON, L. AND FUSTER, V.: Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79: 657-65, 1989.
22. HILPERT, K., ACKERMANN, J., BANNER, D. W., GAST, A., GUBERNATOR, K., HADVÁRY, P., LABLER, L., MÜLLER, K., SCHMID, G., TSCHOPP, T. B. AND VAN DE WATERBEEMD, H.: Design and synthesis of potent and highly selective thrombin inhibitors. J. Med. Chem. 37: 3889-3901, 1994.
23. INAUEN, W., BAUMGARTNER, H. R., BOMBELI, T., HAEBERLI, A. AND STRAUB, P. W.: Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood. Arteriosclerosis 10: 607-15, 1990.
24. JACKSON, C. V., GAIL CROWE, V., FRANK, J. D., WILSON, H. C., COFFMAN, W. J., UTTERBACK, B. G., JAKUBOWSKI, J. A. AND SMITH, G. F.: Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. J. Pharmacol. Exp. Ther. 261: 546-52, 1992.
25. JANG, I. K., GOLD, H. K., LEINBACH, R. C., RIVERA, A. G., FALLON, J. T., BUNTING, S. AND COLLEN, D.: Persistent inhibition of arterial thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor. Cor. Art. Dis. 3: 407-414, 1992.
26. JANG, I. K., GOLD, H. K., ZISKIND, A. A., LEINBACH, R. C., FALLON, J. T. AND COLLEN, D.: Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 81: 219-25, 1990.
27. KAJIYA, F., MATSUOKA, S., OGASAWARA, Y., HIRAMATSU, O., KANAZAWA, S., WADA, Y., TADAOKA, S., TSUJIOKA, K., FUJIWARA, T. AND ZAMIR, M.: Velocity profiles and phasic flow patterns in the non-stenotic human left anterior descending coronary artery during cardiac surgery. Cardiovasc. Res. 27: 845-50, 1993.
28. LAWRENCE, J. B., KRAMER, W. S., MCKEOWN, L. P., WILLIAMS, S. B. AND GRALNICK, H. R.: Arginine-glycine-aspartic acid and fibrinogen γ-chain carboxyterminal peptides inhibit platelet adherence to arterial subendothelium at high wall shear rates. An effect dissociable from interference with adhesive protein binding. J. Clin. Invest. 86: 1715-22, 1990.
29. LEFKOVITS, J., TOPOL, E. J.: Direct thrombin inhibitors in cardiovascular medicine. Circulation 90: 1522-1536, 1994.
30. LIDÓN, R. M., THÉROUX, P., JUNEAU, M., ADELMAN, B. AND MARAGANORE, J.: Initial experience with a direct antithrombin, hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 88: 1495-1501, 1993.
31. 2Cl in baboons. Blood 81: 1762-70, 1993.
32. NEUHAUS, K. L., ESSEN, R. V., TEBBE, U., JESSEL, A., HEINRICHS, H., MÄURER, W., DORING, W., HARMJANZ, D., KÖTTER, V., KALHAMMER, E., SIMON, H. AND HORACEK, T., Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer und Krankenhausärzte (ALKK). Circulation 90: 1638-1642, 1994.
33. ROUX, S., CARTEAUX, J. P., HESS, P. AND CLOZEL, J. P.: Experimental carotid thrombosis in the guinea pig. Thromb. Haemost. 71: 252-256, 1994.
34. ROUX, S. P., SAKARIASSEN, K. S., TURITTO, V. T. AND BAUMGARTNER, H. R.: Effect of aspirin and epinepnrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models. Arterioscler. Thromb. 11: 1182-91, 1991.
35. ROUX, S. P., TSCHOPP, T. B., KUHN, H., STEINER, B. AND HADVÁRY, P.: Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J. Pharmacol. Exp. Ther. 264: 501-508, 1993.
36. SABER, R. S., EDWARDS, W. D., BAILEY, K. R., MCGOVERN, T. W., SCHWARTZ, R. S. AND HOLMES, D. R.: Coronary embolization after balloon angioplasty or thrombolytic therapy: An autopsy study of 32 cases. J. Am. Coll. Cardiol. 22: 1283-1288, 1993.
37. TEIEN, A. N. AND LIE, M.: Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb. Res. 10: 399-410, 1977.
38. Topol, E. J., Bonan, R., Jewitt, D., Sigwart, U., Kakkar, V. V., Rothman, M., de Bono, D., Ferguson, J., Willerson, J. T., Strony, J., Ganz, P., Cohen, M. D., Raymond, R., Fox, I., Maraganore, J. and Adelman, B.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87:1 622-9, 1993.
39. TRIPODI, A., CHANTARANGKUL, V., ARBINI, A. A., MOIA, M. AND MANNUCCI, P. M.: Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb. Haemost. 70: 286-288, 1993.
40. VAN DER BOS, A. A., DECKERS, J. W., HEYNDRICKX, G. R., LAARMAN, G. J., SURYAPRANATA, H., ZIJLSTRA, F., CLOSE, P., RIJNIERSE, J. J. M. M., BULLER, H. R. AND SERRUYS, P. W.: Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 88: 2058-2066, 1993.
41. WEISS, H. J., TURITTO, V. T. AND BAUMGARTNER, H. R.: Effect of shear rate on platelet interaction with subendothemim in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J. Lab. Clin. Med. 92: 750-764, 1978.
42. WILLERSON, J. T., GOLINO, P., EIDT, J., CAMPBELL, W. B AND BUJA, L. M.: Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implications. Circulation 80: 198-205, 1989.